Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

NCT05996185 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

T Cell Lymphoma
T-cell Lymphoma

Interventions

DRUG: Mogamulizumab
DRUG: DA-EPOCH Protocol
DRUG: CHOEP protocol

Sponsor

Yale University

Collaborators

[object Object]